Aura Biosciences, Inc. — Director's Dealing 2021

Nov 4, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Aura Biosciences, Inc. (AURA)
CIK: 0001501796
Period of Report: 2021-11-02

Reporting Person: Medicxi Ventures Management (Jersey) Ltd (10% Owner)
Reporting Person: Medicxi Growth I LP (10% Owner)
Reporting Person: Medicxi Growth Co-Invest I LP (10% Owner)
Reporting Person: Medicxi Growth I GP Ltd (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-02	Common Stock	C	2275827	—	Acquired	2275827	Indirect
2021-11-02	Common Stock	P	693525	$14.00	Acquired	2969352	Indirect
2021-11-02	Common Stock	C	54065	—	Acquired	54065	Indirect
2021-11-02	Common Stock	P	16475	$14.00	Acquired	70540	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-02	Series D-1 Convertible Preferred Stock	$	C	1650676	Disposed		Common Stock (1650676)	Indirect
2021-11-02	Series D-2 Convertible Preferred Stock	$	C	373606	Disposed		Common Stock (373606)	Indirect
2021-11-02	Series E Convertible Preferred Stock	$	C	251545	Disposed		Common Stock (251545)	Indirect
2021-11-02	Series D-1 Convertible Preferred Stock	$	C	39214	Disposed		Common Stock (39214)	Indirect
2021-11-02	Series D-2 Convertible Preferred Stock	$	C	8876	Disposed		Common Stock (8876)	Indirect
2021-11-02	Series E Convertible Preferred Stock	$	C	5975	Disposed		Common Stock (5975)	Indirect

Footnotes

F1: The number of shares of Common Stock contained in Column 4 of Table I, Rows 1 and 3, are the combined total of each share of Series D-1 Convertible Preferred Stock, Series D-2 Convertible Preferred Stock and Series E Convertible Preferred Stock which immediately prior to the closing of the Issuer's initial public offering ("IPO") converted into shares of the Issuer's Common Stock, on a 13.7-for one basis without payment or further consideration and had no expiration date.

F2: Held by Medicxi Growth I LP, a Jersey limited partnership ("Medicxi Growth I"). Medicxi Growth I GP Limited, a Jersey limited liability company ("MGI GP"), is the sole managing general partner of Medicxi Growth I, and Medicxi Ventures Management (Jersey) Limited, a Jersey limited liability company ("Medicxi Manager") is the sole manager of Medicxi Growth I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.

F3: Held by Medicxi Growth Co-Invest I LP, a Jersey limited partnership ("Medicxi Growth Co-Invest I"). MGI GP is the sole managing general partner of Medicxi Growth Co-Invest I, and Medicxi Manager is the sole manager of Medicxi Growth Co-Invest I. The Reporting Persons disclaim Section 16 beneficial ownership of the securities held by Medicxi Growth Co-Invest I, except to the extent of their respective pecuniary interest therein, if any, and this report shall not be deemed to be an admission that they have beneficial ownership of such shares for Section 16 or any other purpose.

F4: Immediately prior to the closing of the IPO, the Series D-1 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-1 Convertible Preferred Stock had no expiration date.

F5: Immediately prior to the closing of the IPO, the Series D-2 Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series D-2 Convertible Preferred Stock had no expiration date.

F6: Immediately prior to the closing of the IPO, the Series E Convertible Preferred Stock automatically converted on a 13.7-for one basis into Common Stock without payment or further consideration. The Series E Convertible Preferred Stock had no expiration date.